FCM
APLS

Flinton Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

Flinton Capital Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$38K Buy
+1,564
New +$43K ﹤0.01% 837
2019
Q1 		– Sell
-2,754
Closed -$36K – 876
2018
Q4 		$36K Buy
+2,754
New +$42.3K ﹤0.01% 810

Other funds holding APLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Flinton Capital Management's APLS Position: Q3 2019 in Review

Flinton Capital Management opened a new position in Apellis Pharmaceuticals (APLS) in Q3 2019: 1,564 shares worth $38K. The stake represents ﹤0.01% of the portfolio and ranks #837 among its holdings. This is a return to the name: Flinton Capital Management previously reported a position in APLS as recently as Q4 2018.

Flinton Capital Management first reported a position in APLS in Q4 2018 and has held it in 2 quarters since. 129 funds tracked by Wall St. Rank hold APLS as of Q3 2019.

  • Flinton Capital Management held 1,564 shares of Apellis Pharmaceuticals worth $38K as of Q3 2019.
  • Apellis Pharmaceuticals was a new Flinton Capital Management position in Q3 2019.
  • Apellis Pharmaceuticals made up ﹤0.01% of Flinton Capital Management's portfolio in Q3 2019, its #837 holding.
  • Flinton Capital Management first reported a position in Apellis Pharmaceuticals in Q4 2018 and has held it in 2 quarters since.
  • 129 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2019.

Based on Flinton Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.